A Study of FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab
This study is to verify the advantage of FOLFOXIRI plus cetuximab over FOLFOXIRI plus bevacizumab as the first-line therapy in metastatic colorectal cancer patients with RAS wild-type tumors.
Colorectal Cancer
DRUG: fluorouracil|DRUG: Leucovorin|DRUG: irinotecan|DRUG: oxaliplatin|BIOLOGICAL: bevacizumab|BIOLOGICAL: cetuximab
Best deepness of response, The maximum tumor shrinkage rates by Response Evaluation Criteria in Solid Tumors (RECIST) throughout the treatments, up to 2 years
Early tumor shrinkage, The rates of tumor shrinkage by RECIST at 8 weeks, at 8 weeks|Response rate, up to 2 years|Deepness of response, The tumor shrinkage rates by RECIST at 4 months, at 4 months|Overall survival, up to 2 years|Progression free survival, up to 2 years|Rate of curatively resected metastatic lesion, up to 2 years|Number of adverse events, up to 2 years
This study is to verify the advantage of FOLFOXIRI plus cetuximab over FOLFOXIRI plus bevacizumab as the first-line therapy in metastatic colorectal cancer patients with RAS wild-type tumors. In this study the investigators employed deepness of response as a primary endpoint.